title: [Clinical efficiency of Vasonat in neurometabolic therapy of patients with ischemic stroke at early rehabilitation period].
abstract: Research of efficiency and safety of Vasonat has been carried out. 31 patients aged 46-75 years who had had hemispheric athero- thrombotic or hemodynamic schemic stroke with moderate severity and being treated in 2-5-month of early rehabilitation period have been observed. The control group of patients received placebo. Results of the study, 4 weeks treatment using Vasonat in the dosage of 500 mg/day have shown positive effect on common signs of the disease by decreasing headache intensity, dizziness, a nausea, and on focal neurological symptoms by decreasing hemiparesis degree; psychoemotional and mnestic activity (main memory and attention) improved as well. It was more distinct in patients with localization of the stroke in the right hemisphere of the brain. It was also noted more rapid improvement of motion function and quality of life of patients.
authors.forename: G B
authors.initials: GB
authors.lastname: Abasova
authors.forename: G U
authors.initials: GU
authors.lastname: Tyksanbaeva
authors.forename: D B
authors.initials: DB
authors.lastname: Orazalieva
authors.forename: S K
authors.initials: SK
authors.lastname: Kasymova
mesh_terms: D000255:Adenosine Triphosphate / Q000819:agonists* / Q000378:metabolism; D000368:Aged; D001921:Brain / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D002317:Cardiovascular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003071:Cognition / Q000187:drug effects; D004244:Dizziness / Q000517:prevention & control; D004734:Energy Metabolism / Q000187:drug effects*; D005260:Female; D005500:Follow-Up Studies; D006261:Headache / Q000517:prevention & control; D006801:Humans; D007623:Kazakhstan; D008297:Male; D008568:Memory / Q000187:drug effects; D008763:Methylhydrazines / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D009043:Motor Activity / Q000187:drug effects; D010291:Paresis / Q000517:prevention & control; D011581:Psychological Tests; D011788:Quality of Life / Q000523:psychology; D020521:Stroke / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D000071939:Stroke Rehabilitation; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; D008763:Methylhydrazines; D000255:Adenosine Triphosphate